A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.
Journal: Schizophrenia research
Volume: 266
Issue:
Year of Publication: 2024
Affiliated Institutions:
Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan , CX Utrecht, the Netherlands. Electronic address: I.E.Slot-@umcutrecht.nl.
Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan , CX Utrecht, the Netherlands. Electronic address: H.H.vanHell-@umcutrecht.nl.
Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan , CX Utrecht, the Netherlands; Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box , New York, NY -, United States of America. Electronic address: I.Winter@umcutrecht.nl.
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London SE AF, United Kingdom. Electronic address: paola.dazzan@kcl.ac.uk.
Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan , CX Utrecht, the Netherlands. Electronic address: A.Maat@umcutrecht.nl.
Amsterdam UMC, University of Amsterdam, Psychiatry, Department Early Psychosis, Meibergdreef , Amsterdam, the Netherlands. Electronic address: l.dehaan@amsterdamumc.nl.
CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Spain; Department of Psychiatry, University of Sevilla. Hospital Universitario Virgen del Rocio, IBiS-CSIC, Sevilla, Spain. Electronic address: benedicto.crespo@unican.es.
Centre for Neuropsychiatric Schizophrenia Research (CNSR) & Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark; University of Copenhagen, Faculty of Health and Medical Sciences, Dept. of Clinical Medicine, Copenhagen, Denmark. Electronic address: birte.glenthoj@cnsr.dk.
Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH HF, United Kingdom. Electronic address: s.lawrie@ed.ac.uk.
Centre for Neuroimaging & Cognitive Genomics (NICOG), Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland. Electronic address: colm.mcdonald@nuigalway.ie.
Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany. Electronic address: oliver.gruber@med.uni-heidelberg.de.
Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, the Netherlands; Mondriaan Mental Health Centre, Maastricht, the Netherlands. Electronic address: t.vanamelsvoort@maastrichtuniversity.nl.
Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón (IiSGM), School of Medicine, Universidad Complutense, Centro de Investigación Biomédica en Red del área de Salud Mental (CIBERSAM), Madrid, Spain. Electronic address: carango@hggm.es.
Department of Psychiatry, University of Marburg, Rudolf-Bultmann-Straße , D- Marburg, Germany. Electronic address: kircher@med.uni-marburg.de.
Orygen, Poplar Road, Parkville, Victoria, Melbourne, Australia; Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: barnaby.nelson@orygen.org.au.
University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, Naples, Italy.
Department of Psychiatry, Sheba Medical Center, Tel Hashomer , Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: mweiser@netvision.net.il.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria. Electronic address: gabriele.sachs@meduniwien.ac.at.
Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland. Electronic address: anke.maatz@pukzh.ch.
Department of Psychiatry, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil.
Department of Psychiatry, Seoul National University College of Medicine, Dahakno, Jongno-gu, Seoul, Republic of Korea. Electronic address: kwonjs@snu.ac.kr.
Department of Psychiatry, McGill University, Montreal, Canada. Electronic address: romina.mizrahi@mcgill.ca.
Department of Psychiatry, University of Oxford, Oxford, United Kingdom. Electronic address: philip.mcguire@psych.ox.ac.uk.
Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan , CX Utrecht, the Netherlands; Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box , New York, NY -, United States of America. Electronic address: rene.kahn@mssm.edu.
Abstract summary
We examined the course of illness over a 12-month period in a large, international multi-center cohort of people with a first-episode schizophrenia spectrum disorder (FES) in a naturalistic, prospective study (PSYSCAN).Patients with a first episode of schizophrenia, schizoaffective disorder (depressive type) or schizophreniform disorder were recruited at 16 institutions in Europe, Israel and Australia. Participants (N = 304) received clinical treatment as usual throughout the study.The mean age of the cohort was 24.3 years (SD = 5.6), and 67 % were male. At baseline, participants presented with a range of intensities of psychotic symptoms, 80 % were taking antipsychotic medication, 68 % were receiving psychological treatment, with 46.5 % in symptomatic remission. The mean duration of untreated psychosis was 6.2 months (SD = 17.0). After one year, 67 % were in symptomatic remission and 61 % were in functional remission, but 31 % had been readmitted to hospital at some time after baseline. In the cohort as a whole, depressive symptoms remained stable over the follow-up period. In patients with a current depressive episode at baseline, depressive symptoms slightly improved. Alcohol, tobacco and cannabis were the most commonly used substances, with daily users of cannabis ranging between 9 and 11 % throughout the follow-up period.This study provides valuable insight into the early course of a broad range of clinical and functional aspects of illness in FES patients in routine clinical practice.
Authors & Co-authors:
Slot
van Hell
Rossum
Dazzan
Maat
de Haan
Crespo-Facorro
Glenthøj
Lawrie
McDonald
Gruber
van Amelsvoort
Arango
Kircher
Nelson
Galderisi
Weiser
Sachs
Maatz
Bressan
Kwon
Mizrahi
McGuire
Kahn
Study Outcome
Source Link: Visit source